Skip to main content
Monday, November 16, 2026Nov 16

AbbVie raises guidance after 1Q sales beat

This Saturday, Jan. 24, 2015 photo shows the exterior of Abbvie, in Lake Bluff, Ill.  AbbVie Inc. on Thursday, April 23, 2015 reported first-quarter net income of $1.02 billion. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 63 cents. Earnings, adjusted for severance costs and non-recurring costs, were 94 cents per share.    (AP Photo/Nam Y. Huh)
This Saturday, Jan. 24, 2015 photo shows the exterior of Abbvie, in Lake Bluff, Ill. AbbVie Inc. on Thursday, April 23, 2015 reported first-quarter net income of $1.02 billion. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 63 cents. Earnings, adjusted for severance costs and non-recurring costs, were 94 cents per share. (AP Photo/Nam Y. Huh)

WASHINGTON (AP) – Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira.

However, U.S. sales of the company’s recently approved hepatitis C pill came in below expectations, underscoring concerns that the company is too reliant on Humira.

Sales of Humira, which is the world’s top-selling prescription drug, increased 18 percent to $3.1 billlion. Humira is approved to treat more than a dozen conditions including rheumatoid arthritis, psoriasis and Crohn’s Disease. But it will start losing patent protection next year and could eventually face competition from Amgen Inc., which is developing a biosimilar version of the drug.

That has focused attention on other AbbVie drugs with blockbuster potential, including Viekira Pak, a new hepatitis C medication approved in the U.S. in December. Company executives have predicted Viekira could reach annual sales of $3 billion by the end of 2015 with further growth in 2016 as the drug expands into new countries.

But U.S. sales of $138 million in the first quarter came in below expectations of $215 million, on average, according to a survey compiled by analyst Robyn Karnauskas of Deutsche Bank.